ѻý

Skeptical Cardiologist: Classifying Heart Failure

<ѻý class="mpt-content-deck">— Anthony Pearson, MD, reviews the latest trials and mandates
MedpageToday
image

For reasons that are unclear to me, ICD-10 was foisted on physicians in 2015 and mandated by CMS.

Now, when classifying heart failure one is consistently badgered by hospital coding monitors to specify whether a patient has systolic heart failure (HF), diastolic HF -- I50.3 (diastolic [congestive] HF) -- or combined systolic and diastolic HF.

The preferred term for diastolic heart failure is now heart failure with preserved ejection fraction (HFpEF), or "huff puff," because most of these patients don't have anything that clearly documents "diastolic dysfunction," and it has become clear in recent years that many of these patients are limited, not by cardiac dysfunction but rather, by key non-diastolic features such as limited systolic reserve, abnormal volume regulation, and maladaptive ventricular-arterial interaction

A recent of inhaled inorganic nitrites presented at the American College of Cardiology meeting in Orlando further emphasizes (a) how complicated the diagnosis of HFpEF is; and (b) how ineffective all drugs are for treating it.

The INDIE investigators hypothesized that inorganic nitrite, which restores nitric oxide, would improve exercise capacity and clinical status in patients with HFpEF, given evidence suggesting that impaired nitric oxide signaling plays a role in HF.

For the INDIE-HFpEF trial, researchers across 20 centers participating in the National Heart, Lung, and Blood Institute Heart Failure Clinical Research Network randomized 105 patients to inhaled nitrite versus placebo in a cross-over trial.

The results were disappointing, as the drug had no effect on peak exercise capacity measured by cardiopulmonary exercise testing and did not increase daily activity or patient-reported quality of life or decrease cardiac congestion.

I pulled up the complete list of 12 inclusion and 21 exclusion criteria for this , and these give us an idea of how complicated the HFpEF diagnosis is.

It's interesting that inclusion criterion #4 contains the only mention of Echo/Doppler criteria.

To be considered HFpEF, patients had to have one of the following:

  • Previous hospitalization for HF with radiographic evidence (pulmonary venous hypertension, vascular congestion, interstitial edema, pleural effusion) of pulmonary congestion
  • Catheterization-documented elevated filling pressures at rest (PCWP ≥15 or LVEDP ≥18) or with exercise (PCWP ≥25)
  • Elevated NT-proBNP (>400 pg/mL) or BNP (>200 pg/mL)
  • Echo evidence of diastolic dysfunction/elevated filling pressures manifest by medial E/e' ratio ≥15 and/or left atrial enlargement and chronic treatment with a loop diuretic for signs or symptoms of HF

An actual measurement of diastolic function of the myocardium (say, tau for relaxation or stiffness constant for compliance) is clearly not required for the diagnosis of HFpEF and is not really measurable by noninvasive parameters.

The echo parameter of E/e' >15 is primarily a measure of preload (and it is fairly inaccurate in patients with normal EF).

I see the following as the take-home points from this trial:

  1. Another potential drug treatment for HFpEF has failed, joining the dozens already that don't help
  2. HFpEF is not synonymous with myocardial diastolic dysfunction
  3. Echo/Doppler diastolic parameters are primarily useful for vaguely estimating LV preload and play only a limited role in diagnostic criteria for HFpEF

is a private-practice noninvasive cardiologist, and medical director of echocardiography at St. Luke's Hospital in St. Louis. He blogs on nutrition, cardiac testing, quackery, and other things worthy of skepticism at , where a version of this post first appeared.